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ABSTRACT
Background and the purpose of the study: Candida species are the agents of local and systemic 
opportunistic infections and have become a major cause of morbidity and mortality in the last 
few decades. Azole resistance in Candida krusei (C. krusei) species appears to be the result of 
gene alterations in relation to the ergosterol biosynthesis pathway, as well as efflux pumps. The 
main objective of this study was to examine the RNA expression of ERG11 in C. krusei which 
had been identified to be resistance to azoles.
Methods: The ERG11 mRNA expression was investigated in four Iranian clinical isolates of       
C. krusei, which were resistant to fluconazole and itraconazole by a semiquantitative RT-PCR. 
Results: The mRNA expression levels were observed in all four isolates by this technique. 
Furthermore, it was found that ERG11 expression levels vary among four representative isolates 
of C. krusei. Although DNA sequencing revealed no significant genetic alteration in the ERG11 
gene, one heterozygous polymorphism was observed in two isolates, but not in others. This 
polymorphism was found in the third base of codon 313 for Thr (ACT>ACC). 
Major conclusion: Even though such a polymorphism creates a new Ear1 restriction site, no 
significant effect was found on the resistance of C. krusei to azoles. Results of this investigation are 
consistent with previous studies and may provide further evidence for the genetic heterogeneity 
and complexity of the ergosterol biosynthetic pathway or efflux pumps. 
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INTRODUCTION
Candida species (spp) are agents of local and 
systemic opportunistic infections worldwide and 
have been described as the fourth leading cause 
of nosocomial bloodstream infections (BSIs). 
Moreover, treatment failures and development of 
the drug resistance have frequently been reported 
(1). Although C. albicans is the most important 
cause of candidemia, an increasing number of 
infections due to non Candida albicans species 
such as C. glabrata and C. krusei have also been 
reported (2). On the basis of reports 95% of   
Candida BSIs are associated with C. albicans, C. 
parapsilosis, C. glabrata, and C. tropicalis species 
and 12-14 of other Candida spp are involved in 
5% of BSIs (3-5). A slight increase of BSIs due 
to non-albicans species has been reported, and C. 
krusei accounts for 24% of all Candida nosocomial 
bloodstream infections. It is known that this 
species has a tendency to appear in a setting where 
fluconazole has been administered for prophylaxis 
(5). Colonization and infection with fluconazole-
resistant  Candida spp. has often been observed 
among high risk patients with hematological 
malignancies under the selective routine fluconazole 
prophylaxis (6, 7). C. krusei has been detected as 
an uncommon and potentially multi-drug resistant 
(MDR) pathogen. In vitro antifungal testing has 
shown a considerable reduction in susceptibility 
of C. krusei to fluconazole (2.9% sensitive) and 
amphotriecin B (8% of all isolates), and the emerging 
pathogenicity of this organism is of increasing 
public health concern (8). It has been demonstrated 
that multiple mechanisms are involved in azole 
resistance,  including  overexpression  of  several 
genes encoding efflux pumps such as CDR1, CDR2 
and MDR1 (multi-drug resistance), which lead to 
reduced intracellular accumulation of fluconazole 
and overexpression of the ERG11 gene, coding for 
the sterol 14α-demethylase (9, 10).
Some studies have proposed reduction in 
susceptibility  of  sterol  14α-demethylase  to 
fluconazole as major resistance mechanism in      C. 
krusei  (11-14).  The  present  study  was  aimed  to 
investigate the expression of ERG11 in four Iranian 
C. krusei isolates.
MATERIAL AND METHODS
Fungal strains 
Four fluconazole and itraconazole resistant C. krusei 
strains were included in the present study (Table1). Upregulation of the ERG11 Gene in Candida krusei by Azoles
These strains were isolated from cancerous patients 
with oropharyngeal Candida infections during 
2006-2008  and  had  been  identified  previously 
(15). The susceptibility testing of the isolates 
to  fluconazole  and  itraconazole  was  performed 
according to the National Committee for Clinical 
Laboratory  Standards  M27-A  (NCCLS)  by  broth 
microdilution  method  (16).  Susceptibility  tests 
were carried out in RPMI 1640 medium (Sigma-
Aldrich, USA) buffered to pH 7.0 with 0.165 M 
morpholinepropanesulfonic  acid  (MOPS).  The 
MICs were defined as concentrations of the drug 
that reduced growth by 80% compared to that 
of organisms grown in the absence of the drug. 
NCCLS-recommended  quality  control  (Candida 
krusei ATCC 6258) was included in each test run, 
and MICs were within the recommended range for 
each test. The isolates had been stored in glycerol/
water  at  -80°C  until  used.  The  inocula  for  each 
individual  experiment  were  prepared  from  these 
stocks.
Total RNA and cDNA synthesis extraction
C. krusei cells were grown on Sabouraud dextrose 
agar at 37°C for 24 hrs. Two to three fresh colonies 
were transferred to yeast peptone dextrose (YPD) 
broth (yeast extract 1%, peptone 2%, dextrose 2%), 
(Suprapur, Merck, Germany) at the same temperature 
for 48 hrs. 
Total  RNA  was  isolated  from  exponential-phase 
of  the  YPD  broth  cultures  using  RNeasy  Mini 
kit (Qiagen) according to the manufacturer’s 
instruction. Quantification of RNA was performed 
by absorbance at 260 nm using a Spectrophotometer 
(Biophotometer).  The  mean  RNA  concentration 
and  the  mean  ratio  for  OD260/280  were  421+6 
ng/µl  and  1.8+0.04,  respectively.  For  cDNA 
synthesis, 10 μl of total RNA was heated in 80°C 
for 10 min followed by cooling on ice. The master 
mixture contained 4 μl of 5x reverse transcriptase 
(RT)  buffer,  10  mM  of  each  dNTP,  20  pmol/μl 
random primer, 20 U RNase inhibitor (Fermentas, 
Burlington  Canada),  200  U  of  Moloney  Murine 
Leukemia Virus (MMuLV) Reverse Transcriptase 
(Fermentas,  Burlington  Canada),  and  1.5  μl  of 
DEPC-treated  water.  The  cDNA  synthesis  was 
performed  under  following  conditions:  42°C  for 
60 min, 70°C for 10 min, and finally cooling to                         
4°C. The integrity of cDNA was checked using the 
house  keeping  gene  18sRNA  primers  (as  shown 
in table 2) which amplify region 1433-1639 (GB.
EU348783.1). Samples with similar cDNA quality 
through  18sRNA  PCR  were  stored  at  -70°C  for 
further investigation.
PCR amplification of the ERG11 gene was conducted 
on samples using 1 µl of cDNA, specific forward and 
reverse primers corresponding to ERG11gene (Table 
2), dNTP, MgCl2, Taq DNA polymerase, and buffer 
(CinnaGen,  Tehran,  Iran).  The  thermocycling  was 
performed using a Touch-Down amplification program 
on 2720 Thermal Cycler, ABI . The PCR condition 
was as the same as previously described (17).
Strain Predisposing factor Site of isolation 
MICa (µg/ml)
FLCb      ITCc
C. krusei 2     Carcinoma (lung) Orophrynex  64          1
C. krusei 118 Lymphoma “ 128        1
C. krusei 124 Lymphoma “ 64 2
C. krusei 144 Leukaemia “ 64 2
a: Minimum Inhibitory Concentration; b:Fluconazole; c:Itraconazole
Table 1. Characteristics of Candida krusei strains used in this study.
Primer  Primer Sequences Accession  PCR Product 
Name 5’→3’ Number Sizes (bp)
Semi-Quantitative RT-PCR  Primers
18SCF
18SCR
5’-GACGGAGCCAGCGAGTATAA-3′
5’-GGGCTCACTAAGCCATTCAA-3′
GB.EU348783.1 206
ERG11F
ERG11R
5′-AATGGGTGGTCAACATACTT-3′
5′-TGGTGGTAGACATAGATGTATT-3’
DQ903905  508
Sequencing Primers
ER11SF
ER11SR
5′-GTTTACGGAAAACCTTAC- 3′
5’-GGTACATCTATGTCTACCACCACCA-3′
DQ903905 1218
Table 2. List of primers used in this study.Tavakoli et al / DARU 2010 18 (4) 276-280
Semi-quantitative RT-PCR 
Semi-quantitative  RT-PCR  was  conducted  by  the 
reported method with minor modification (18, 19).
Briefly,  specific  primers  corresponding  to  ERG11 
and  18s  rRNA  mRNA  sequences  were  designed. 
Appropriate dilutions of the samples were determined 
for each cDNA to make sure that examined transcripts 
and 18sRNA (internal control) amplification was in 
the exponential phase of the reaction. 
DNA sequencing
For mutation screening, genomic DNA was extracted 
from 5×107 cells using DNGPLUS kit (CinnaGen, 
Tehran, Iran). PCR amplification of whole ERG11 
gene  was  carried  out  using  specific  primer  pairs 
(Table 2).  To detect any mutation, the PCR product 
was subjected to direct sequencing (Gen-Fanavaran, 
Tehran, Iran). Sequence  data  searches  were 
performed  in  non-redundant  nucleic  and  protein 
databases BLAST (http://www.ncbi.nlm.nih.gov/
BLAST).
RESULTS
Four  C. krusei  isolates  exhibited  ERG11  mRNA 
overexpression at various levels. A semiquantitative 
RT-PCR  was  used  to  compare  positive  results  of 
expression levels as: no expression (0), mild (1+), 
moderate (2+), high expression (3+) and the highest 
expression (+4) (Fig. 1).  
Direct  DNA  sequencing  was  carried  out  for 
investigation of the molecular bases of ERG11 
overexpression.  Amplified  PCR  products  of                               
the  complete  coding  sequences  of  this  gene 
from four C. krusei isolates were sequenced. The 
chromatogram of ERG11 DNA sequencing (Figures. 
2A, B) indicated a heterozygous base-substitution 
in two C. krusei isolates, in which a heterozygous 
change had occurred in the third base of codon 313 
for Thr (DQ903905).  Figure 2 C shows homozygous 
condition of the mentioned polymorphism.  Although 
this genetic alteration (ACT>ACC) can not change 
the amino acid sequence of the ERG11 protein, it 
leads to the creation of an Ear1 restriction enzyme 
recognition site. Also, direct PCR sequencing of other 
samples revealed no mutation (data not shown).
DISCUSSION
Ergosterol  biosynthesis  is  a  complex  metabolic 
pathway. So far, the involvement of several 
genes encoding enzymes in this pathway has 
been identified. It has been well documented that 
some of these metabolic steps are critical for cell 
viability. For instance, ERG11 deletions are lethal 
in S. cerevisiae (9), whereas no specific gene in C. 
krusei has been reported to exert significant effect. 
Previous studies have shown the role of ERG11 
upregulation  in  fluconazole-resistant  clinical 
isolates of Candida spp. (20). Several lines of 
evidence suggested that other genes of the sterol 
biosynthetic pathway (ERG3) and another pathway 
such as efflux pumps also play critical roles in the 
antifungal resistance of yeast (21-24). Moreover, 
some studies have shown involvement of efflux 
pumps in increasing the levels of resistance of 
C. krusei to azoles (25-30). In this study a semi- 
quantitative  RT-PCR  employing  18sRNA  as  an 
internal control was performed for detection of   
the levels of ERG11 expression in clinical isolates 
of  C. krusei. All isolates revealed variations  in 
ERG11 expression levels. To date, more than 20 
genes have been found that are involved in azole 
resistance. 
In general, ERG genes were found to be unregulated 
by either the reduction of a late product; or an 
accumulation of an early substrate or toxic sterol 
intermediates of the ergostrol biosynthetic pathway. 
It has been clearly demonstrated that several 
different inhibitors can affect different enzymes 
of this pathway which lead to upregulation of 
ERG genes in S. cerevisiae and Candida spp. 
Moreover, most previous studies have shown 
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Figure 1. ERG11 mRNA expression.
 RT-PCR products of ERG11 gene of clinical isolates of C. krusei, 
resistant  to  fluconazole  and  itraconazole  on  1.8%  agarose  gel 
stained with ethidium bromide. Lanes 1(+1), 2 (+4), 3 (+3) and 
4  (+2):  indicate  different  levels  of  ERG11  mRNA  expression 
(508bp); lane 5: negative control (water).18srRNA (206bp) was 
used as a positive control.
18s RNA
206bp
ERG11
 508bp
Figure 2. Mutation analysis of the ERG11 genomic DNA. 
(A, B) A heterozygous polymorphism in codon 313 for 
Thr  (ACT>ACC)  in  which  T→C  at  position  939  of  mRNA 
(DQ903905) was found in two samples. (C) A chromatogram 
from one of the samples indicates wild type homozygous 
condition.
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that the levels of ergosterol or other intermediate 
sterols which are formed in this pathway might 
be responsible for regulation of ERG expression 
in these  species (20, 30). The exact molecular 
mechanism behind the upregulation of ERG11 
gene in response to azoles and other antifungal 
drugs is not completely understood. Therefore, 
it was considered to investigate whether various 
amino acid substitutions or probable mutations, 
cause  enhanced  expression  of  ERG11 and 
changes  in  azole  susceptibility  (31).  Our  DNA 
sequence  analysis  of  the  ERG11 coding region 
displayed a heterozygous base substitution T→C 
(ACT>ACC) in two C. krusei isolates. However, 
this genetic alteration cannot lead to a change in 
the amino acid sequence of ERG11 protein which 
creates an Ear1 restriction enzyme recognition 
site. It has been well documented that protein–
DNA interactions play a fundamental role in cell 
biology (32). Therefore, this polymorphism might 
play a critical role in the transcriptional regulation 
of genes which might be involved in the processes 
of ergosterol biosynthesis. 
In addition, data of this study revealed that C. krusei 
is a diploid organism, which is in agreement with 
most recent findings which have identified different 
alleles for ERG11 gene in C. kruse strains (27). 
CONCLUSION
The ERG11 overexpression is unlikely to be the 
cause of azole resistance in C. krusei isolates. A 
potential mechanism for azole resistance could be 
the level of promoter activity which is equivalent 
to the rate of ergosterol or sterol biosynthesis, 
as  it  has  been  confirmed  in  yeasts  and  human 
beings. In fact, it appears that stimulation of the 
ERG11 promoter has arisen in response to sterol 
deprivation or a reduced level of sterol resources. 
It is noteworthy that upregulation of ERG11 
could be affected by its upstream (ERG9, ERG1, 
ERG7) or downstream genes (ERG3,  ERG25). 
Additionally, genetic changes in the ERG11 
promoter region may also modulate levels of the 
expression of genes that are involved in ergosterol 
biosynthesis. Other possibilities to explain ERG11 
overexpression and azole resistance might be due 
to the growth conditions, carbon source and semi-
anaerobic growth of fungal cells.
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